Dengue and chikungunya vaccines given together or separately
Part of Infections clinical trials.
This trial tests whether giving the dengue and chikungunya vaccines together is as safe and effective as giving them separately. If you are a healthy adult, you may be able to help find a more convenient way to protect against these diseases.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 59 years old.
- You need to be able to give informed consent and follow study procedures, including blood draws.
- You must not have had dengue or chikungunya in the past, nor have received a vaccine for either disease.
- You must be generally healthy, without unstable medical conditions requiring recent hospitalization or treatment changes.
- You must not have a weakened immune system (due to conditions like HIV, cancer treatment, or long-term steroid use).
- If you are a woman of childbearing age, you cannot be pregnant or breastfeeding and must agree to use contraception for 90 days after vaccination.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new dengue vaccine in adults aged 40 to 79 to see if it can protect them from dengue fever. If you are generally healthy and willing to follow the study schedule, you may be able to join.
This study tests an experimental vaccine designed to protect against chikungunya, a mosquito-borne virus that causes fever and joint pain. The trial will evaluate the vaccine's safety and immune response in healthy adults.
This study tests a controlled dengue infection in volunteers who already have immunity to some dengue types. It aims to see how safe it is and how the immune system responds, which could help develop better vaccines.
This study tests how the body responds to a mild, lab-made dengue virus in people who have had dengue before. It looks at how the immune system reacts to a second infection, which may help improve future vaccines and treatments.
This early-stage trial tests a new dengue vaccine in healthy adults. Participants will receive the vaccine and later be exposed to a weakened dengue virus to see if the vaccine protects them, while being closely monitored for safety and immune response.
This trial tests how the dengue virus affects healthy adults who have never been exposed to dengue or similar viruses. You would be given a controlled dose of the virus and closely monitored to help researchers understand the infection and develop better treatments or vaccines.
Hear when a new Dengue trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.